|Description:|| 1. Isorhamnetin - 3 -O -glucuronide exerts anti-inflammatory activity by increasing heme oxygenase-1 (HO-1) expression and by suppressing Jun N-terminal kinase (JNK) and p38 signaling pathways in LPS-challenged RAW264.7 macrophage cells.|
2. Isorhamnetin-3-glucuronide(1 mg/kg i.v.) can progressively reduce mean blood pressure (MBP), measured in conscious spontaneously hypertensive rats (SHR).
3. Isorhamnetin 3-glucuronide can inhibit vascular cell adhesion molecule-1 (VCAM-1) cell surface expression at 2 micromol/L, indicates that it can inhibit the expression of key molecules involved in monocyte recruitment during the early stages of atherosclerosis at physiological concentrations.
|Targets:||HO-1 | JNK | p38MAPK|
|Source:||The herbs of Potentilla discolor Bge.|
|Solvent:||DMSO, Pyridine, Methanol, Ethanol, etc.|
|Storage:||Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).
Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.
Need more advice on solubility, usage and handling? Please email to: firstname.lastname@example.org
|After receiving:||The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.|
|1 mg||5 mg||10 mg||20 mg||25 mg|
|1 mM||2.0309 mL||10.1546 mL||20.3091 mL||40.6182 mL||50.7728 mL|
|5 mM||0.4062 mL||2.0309 mL||4.0618 mL||8.1236 mL||10.1546 mL|
|10 mM||0.2031 mL||1.0155 mL||2.0309 mL||4.0618 mL||5.0773 mL|
|50 mM||0.0406 mL||0.2031 mL||0.4062 mL||0.8124 mL||1.0155 mL|
|100 mM||0.0203 mL||0.1015 mL||0.2031 mL||0.4062 mL||0.5077 mL|
Tetrahedron Volume 62, Issue 29, 17 July 2006, Pages 6862–6868
|Convenient syntheses of metabolically important quercetin glucuronides and sulfates[Reference: WebLink]|
|Synthetic approaches to the major human plasma metabolites of quercetin, quercetin 3′-sulfate and the β-d-glucopyranosiduronic acid derivatives 3′-methylquercetin 3-glucuronide (Isorhamnetin 3-glucuronide), quercetin 3-glucuronide and quercetin 3′-glucuronide are described. This is the first report of the chemical synthesis of quercetin 3′-glucuronide. All procedures start from the same precursor, 4′,7-di-O-benzylquercetin, and all are more convenient than existing methods.|
Plos One, 2012, 7(3):e32673.
|Glucuronidated quercetin lowers blood pressure in spontaneously hypertensive rats via deconjugation.[Pubmed: 22427863 ]|
|We have analyzed the effects on blood pressure and vascular function in vitro of the conjugated metabolites of quercetin (quercetin-3-glucuronide, Q3GA; Isorhamnetin-3-glucuronide, I3GA; and quercetin-3'-sulfate, Q3'S) in spontaneously hypertensive rats (SHR). Q3GA and I3GA (1 mg/kg i.v.), but not Q3'S, progressively reduced mean blood pressure (MBP), measured in conscious SHR. The hypotensive effect of Q3GA was abolished in SHR treated with the specific inhibitor of β-glucuronidase, saccharic acid 1,4-lactone (SAL, 10 mg/ml). In mesenteric arteries, unlike quercetin, Q3GA had no inhibitory effect in the contractile response to phenylephrine after 30 min of incubation. However, after 1 hour of incubation Q3GA strongly reduced this contractile response and this effect was prevented by SAL. Oral administration of quercetin (10 mg/Kg) induced a progressive decrease in MBP, which was also suppressed by SAL. Conjugated metabolites are involved in the in vivo antihypertensive effect of quercetin, acting as molecules for the plasmatic transport of quercetin to the target tissues. Quercetin released from its glucuronidated metabolites could be responsible for its vasorelaxant and hypotensive effect.|